• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
CEL-SCI Corporation - Product Pipeline Review - 2014 - Product Image

CEL-SCI Corporation - Product Pipeline Review - 2014

  • Published: April 2014
  • 40 pages
  • Global Markets Direct

CEL-SCI Corporation - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘CEL-SCI Corporation - Product Pipeline Review - 2014’, provides an overview of the CEL-SCI Corporation’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CEL-SCI Corporation’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s READ MORE >

Table of Contents
Table of Contents
List of Tables
List of Figures
CEL-SCI Corporation Snapshot
CEL-SCI Corporation Overview
Key Information
Key Facts
CEL-SCI Corporation - Research and Development Overview
Key Therapeutic Areas
CEL-SCI Corporation - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
CEL-SCI Corporation - Pipeline Products Glance
CEL-SCI Corporation - Late Stage Pipeline Products
Phase III Products/Combination Treatment Modalities
CEL-SCI Corporation - Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
CEL-SCI Corporation - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
CEL-SCI Corporation - Drug Profiles
Leukocyte Interleukin Injection
Product Description
Mechanism of Action
R&D Progress
LEAPS-H1N1-DC
Product Description
Mechanism of Action
R&D Progress
CEL-1000
Product Description
Mechanism of Action
R&D Progress
CEL-2000
Product Description
Mechanism of Action
R&D Progress
J-HER Vaccine For Breast Cancer
Product Description
Mechanism of Action
R&D Progress
CEL-SCI Corporation - Pipeline Analysis
CEL-SCI Corporation - Pipeline Products by Target
CEL-SCI Corporation - Pipeline Products by Molecule Type
CEL-SCI Corporation - Recent Pipeline Updates
CEL-SCI Corporation - Company Statement
CEL-SCI Corporation - Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
CEL-SCI Corporation, Key Information
CEL-SCI Corporation, Key Facts
CEL-SCI Corporation - Pipeline by Indication, 2014
CEL-SCI Corporation - Pipeline by Stage of Development, 2014
CEL-SCI Corporation - Monotherapy Products in Pipeline, 2014
CEL-SCI Corporation - Partnered Products in Pipeline, 2014
CEL-SCI Corporation - Partnered Products/ Combination Treatment Modalities, 2014
CEL-SCI Corporation - Phase III, 2014
CEL-SCI Corporation - Phase I, 2014
CEL-SCI Corporation - Preclinical, 2014
CEL-SCI Corporation - Pipeline by Target, 2014
CEL-SCI Corporation - Pipeline by Molecule Type, 2014
CEL-SCI Corporation - Recent Pipeline Updates, 2014

List of Figures
CEL-SCI Corporation - Pipeline by Top 10 Indication, 2014
CEL-SCI Corporation - Pipeline by Stage of Development, 2014
CEL-SCI Corporation - Monotherapy Products in Pipeline, 2014
CEL-SCI Corporation - Pipeline by Top 10 Target, 2014
CEL-SCI Corporation - Pipeline by Top 10 Molecule Type, 2014 25

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos